Table 3.
List of publications reporting SPMs’ antitumor activity in murine cancer models.
| SPMs | Cancer Models | Molecules | Effects | References |
|---|---|---|---|---|
| LXA4 | Colorectal cancer | Native | Suppress early development of colorectal cancer (Mϕ) | (38) |
| BML-111 or AT-LXA4 | Inhibit tumor growth | (166, 170) | ||
| Hepatocellular carcinoma | BML-111 | Inhibit tumor growth | (170, 171) | |
| BML-111 | Inhibit EMT and metastasis (Mϕ) | (172) | ||
| BML-111 | Inhibit proliferation, invasion and angiogenesis of cancer cells (Mϕ) | (173) | ||
| Papillomas | Native | Inflammation resolution Reduce the risk of cancer transformation |
(174) | |
| Melanoma | ATL-1, BML-111 | Inhibit tumor growth Alter TAM phenotype in vivo (Mϕ) |
(165, 170) | |
| ATL-1 | Decrease monocyte infiltration in tumor (Mϕ) Alters TAM phenotype in vivo (Mϕ) |
(175) | ||
| Pancreatic | BML-111 | Reduce liver metastases | (176) | |
| RvD1 | Hepatocellular carcinoma | Native | Block CAF pro-tumor effects on tumor growth and metastases | (177) |
| Native | Prevent liver injury and cancer transformation | (178) | ||
| Melanoma | Native | Reduce pulmonary metastasis | (86) | |
| RvD2 | OSCC | Native | Tumor growth reduction (Mϕ) | (179) |
| Lung, Melanoma | Native | Reduce pulmonary metastasis | (86) | |
| RvE1 | Hepatocellular carcinoma | Native | Prevent liver injury and cancer transformation | (178) |
| RvD2, RvD3, RvD4 | Lung, Lymphoma, Melanoma | Native | Reduce metastases and improve survival (preoperative context) | (180) |
| RvD1, RvD2, RvE1 | Lung, Pancreatic cancer, Prostate | Native | Inhibit tumor growth | (86) |
| RvD1, RvD3 | Lung | AT-RvD1, AT-RvD3 | Inhibit tumor growth | (176) |
| MaR1 | Skin inflammation | Native | Prevent cancer risk following UVB irradiation | (181) |